On Tuesday, senior Biden-Harris Administration officials met again with manufacturers and partners of RSV immunizations including Sanofi, AstraZeneca, and Thermo Fisher and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market. This meeting follows numerous in-person and virtual meetings, including last week, to continue to identify ways manufacturers can make more RSV available for infants. Last month, manufacturers released 77,000 additional doses of RSV immunizations for infants following Administration efforts' urging the manufacturers to expedite the availability of doses.
During the meeting, manufacturers and senior administration officials also continued to discuss efforts manufacturers are taking to increase availability of RSV immunizations for the 2024-25 viral season.
The Biden-Harris Administration continues to prioritize access to safe and effective vaccines for all Americans who want them, and continues to encourage Americans to protect themselves and their loved ones by getting vaccinated.
